{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:44:09Z","timestamp":1787312649820,"version":"build-2736575974"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["J 4517-B"],"award-info":[{"award-number":["J 4517-B"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Efficient application of immunotherapy necessitates advanced whole-body imaging techniques to monitor sites of immune cell activation. Deoxycytidine kinase (dCK), a key enzyme in the deoxynucleotide salvage pathway, is upregulated in proliferating immune cells and can be targeted by the radiotracers [\n                    <jats:sup>18<\/jats:sup>\n                    F]FAC (preclinical) and [\n                    <jats:sup>18<\/jats:sup>\n                    F]CFA (clinical), allowing for noninvasive monitoring of immune activation in lymphatic organs via positron emission tomography (PET). In this study, we aimed to assess the efficacy of [\n                    <jats:sup>18<\/jats:sup>\n                    F]FAC in detecting immune activation upon immune checkpoint inhibitor therapy (CIT). In vitro, activated T cells and macrophages exhibited significantly higher [\n                    <jats:sup>18<\/jats:sup>\n                    F]FAC uptake compared to their na\u00efve counterparts. In vivo, preclinical [\n                    <jats:sup>18<\/jats:sup>\n                    F]FAC-PET\/MRI revealed a CIT-induced significant increase in [\n                    <jats:sup>18<\/jats:sup>\n                    F]FAC uptake in tumor-draining lymph nodes (TDLNs) compared to contralateral lymph nodes, independent of tumor responsiveness. This phenomenon was absent in TDLNs of sham-treated experimental mice. Ex vivo cell sorting further confirmed elevated [\n                    <jats:sup>18<\/jats:sup>\n                    F]FAC uptake in T cells from TDLNs following CIT. Consistently, [\n                    <jats:sup>18<\/jats:sup>\n                    F]CFA-PET\/CT imaging in metastatic melanoma patients demonstrated CIT-induced enhanced regional LN uptake. Together, these findings establish a strong correlation between CIT-induced immune activation and [\n                    <jats:sup>18<\/jats:sup>\n                    F]FAC\/[\n                    <jats:sup>18<\/jats:sup>\n                    F]CFA uptake, underscoring the critical role of TDLNs in cancer immuotherapy. The radiotracers [\n                    <jats:sup>18<\/jats:sup>\n                    F]FAC and [\n                    <jats:sup>18<\/jats:sup>\n                    F]CFA provide valuable tools for noninvasive monitoring of immune cell activation, potentially unveiling tumor-microenvironment-related resistance mechanisms and advancing the utility of PET imaging in immunotherapy monitoring and patient stratification.\n                  <\/jats:p>","DOI":"10.1038\/s44303-025-00133-8","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:52:38Z","timestamp":1767707558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Noninvasive in vivo deoxycytidine kinase (dCK)-PET identifies tumor-draining lymph nodes upon immune checkpoint inhibitor therapy"],"prefix":"10.1038","volume":"4","author":[{"given":"C\u00e9cile","family":"Philippe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Cotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D.","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"P\u00f6schel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Knopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Sch\u00f6rg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Gonzalez-Menendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Sonanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Flatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Allen-Auerbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caius G.","family":"Radu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Czernin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Quintanilla-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Hacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd J.","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9119-1970","authenticated-orcid":false,"given":"Manfred","family":"Kneilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"133_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/d41573-019-00182-w","volume":"19","author":"J Xin Yu","year":"2020","unstructured":"Xin Yu, J. et al. Trends in clinical development for PD-1\/PD-L1 inhibitors. Nat. Rev. Drug Discov. 19, 163\u2013164 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"133_CR2","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow, M. A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006\u20132017 (2015).","journal-title":"N. Engl. J. Med."},{"key":"133_CR3","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1200\/JCO.2016.66.9929","volume":"34","author":"S Gettinger","year":"2016","unstructured":"Gettinger, S. et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J. Clin. Oncol. 34, 2980\u20132987 (2016).","journal-title":"J. Clin. Oncol."},{"key":"133_CR4","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540\u20131550 (2016).","journal-title":"Lancet"},{"key":"133_CR5","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277\u20131290 (2018).","journal-title":"N. Engl. J. Med."},{"key":"133_CR6","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.biopha.2018.11.105","volume":"110","author":"N Yaghoubia","year":"2019","unstructured":"Yaghoubia, N., Soltania, A., Ghazvinib, K., Hassaniana, S. M. & Hashemy, S. I. PD-1\/ PD-L1 blockade as a novel treatment for colorectal cancer. Biomed. Pharmacother. 110, 312\u2013318 (2019).","journal-title":"Biomed. Pharmacother."},{"key":"133_CR7","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.ctrv.2015.11.001","volume":"41","author":"X Meng","year":"2015","unstructured":"Meng, X., Huang, Z., Teng, F., Xing, L. & Yu, J. Predictive biomarkers in PD-1\/PD-L1 checkpoint blockade immunotherapy. Cancer Treat. Rev. 41, 868\u2013876 (2015).","journal-title":"Cancer Treat. Rev."},{"key":"133_CR8","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","volume":"37","author":"PA Ott","year":"2019","unstructured":"Ott, P. A. et al. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated with Pembrolizumab Across 20 Cancers: KEYNOTE-028. J. Clin. Oncol. 37, 318\u2013327 (2019).","journal-title":"J. Clin. Oncol."},{"key":"133_CR9","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid, O. et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann. Oncol. 30, 582\u2013588 (2019).","journal-title":"Ann. Oncol."},{"key":"133_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-017-1678-1","volume":"21","author":"F Kroschinsky","year":"2017","unstructured":"Kroschinsky, F. et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit. Care 21, 89 (2017).","journal-title":"Crit. Care"},{"key":"133_CR11","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","volume":"25","author":"L Voorwerk","year":"2019","unstructured":"Voorwerk, L. et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat. Med. 25, 920\u2013928 (2019).","journal-title":"Nat. Med."},{"key":"133_CR12","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","volume":"168","author":"MH Spitzer","year":"2017","unstructured":"Spitzer, M. H. et al. Systemic immunity is required for effective cancer immunotherapy. Cell 168, 487\u2013502.e15 (2017).","journal-title":"Cell"},{"key":"133_CR13","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124507","volume":"23","author":"MF Fransen","year":"2018","unstructured":"Fransen, M. F. et al. Tumor-draining lymph nodes are pivotal in PD-1\/PD-L1 checkpoint therapy. JCI Insight 23, e124507 (2018).","journal-title":"JCI Insight"},{"key":"133_CR14","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","volume":"38","author":"F Dammeijer","year":"2020","unstructured":"Dammeijer, F. et al. The PD-1\/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. Cancer Cell 38, 685\u2013700.e8 (2020).","journal-title":"Cancer Cell"},{"key":"133_CR15","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1007\/s00262-020-02792-5","volume":"70","author":"MJ Melia","year":"2021","unstructured":"Melia, M. J., Manspeaker, M. P. & Thomas, S. N. Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC. Cancer Immunol. Immunother. 70, 2179\u20132195 (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"133_CR16","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1016\/j.cell.2022.09.020","volume":"185","author":"Q Huang","year":"2022","unstructured":"Huang, Q. et al. The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1\/PD-L1 blockade in draining lymph nodes. Cell 185, 4049\u20134066.e25 (2022).","journal-title":"Cell"},{"key":"133_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.trecan.2023.09.006","volume":"10","author":"I Delclaux","year":"2024","unstructured":"Delclaux, I., Ventre, K. S., Jones, D. & Lund, A. W. The tumor-draining lymph node as a reservoir for systemic immune surveillance. Trends Cancer 10, 28\u201337 (2024).","journal-title":"Trends Cancer"},{"key":"133_CR18","doi-asserted-by":"crossref","unstructured":"Wang, Y. et al. Tumor-draining lymph nodes: opportunities, challenges, and future directions in colorectal cancer immunotherapy. J. Immunother. Cancer 12, e0080262024.","DOI":"10.1136\/jitc-2023-008026"},{"key":"133_CR19","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3390\/jcm8050681","volume":"8","author":"A Signore","year":"2019","unstructured":"Signore, A. et al. Immuno-imaging to predict treatment response in infection, inflammation and oncology. J. Clin. Med. 8, 681 (2019).","journal-title":"J. Clin. Med."},{"key":"133_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-019-0078-z","volume":"4","author":"P Wierstra","year":"2019","unstructured":"Wierstra, P. et al. Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer. EJNMMI Radiopharm. Chem. 4, 29 (2019).","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"133_CR21","doi-asserted-by":"publisher","first-page":"7924","DOI":"10.7150\/thno.37924","volume":"9","author":"M Krekorian","year":"2019","unstructured":"Krekorian, M. et al. Imaging of T-cells and their responses during anti-cancer immunotherapy. Theranostics 9, 7924\u20137947 (2019).","journal-title":"Theranostics"},{"key":"133_CR22","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1007\/s00330-018-5814-3","volume":"29","author":"Y Du","year":"2019","unstructured":"Du, Y. et al. Advances in molecular imaging of immune checkpoint targets in malignancies: current and future prospect. Eur. Radiol. 29, 4294\u20134302 (2019).","journal-title":"Eur. Radiol."},{"key":"133_CR23","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s11307-018-1254-3","volume":"20","author":"GO Fruhwirth","year":"2018","unstructured":"Fruhwirth, G. O. et al. The potential of in vivo imaging for optimization of molecular and cellular anti-cancer immunotherapies. Mol. Imaging Biol. 20, 696\u2013704 (2018).","journal-title":"Mol. Imaging Biol."},{"key":"133_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1158\/0008-5472.CAN-15-1707","volume":"76","author":"R Tavar\u00e9","year":"2016","unstructured":"Tavar\u00e9, R. et al. An effective immune-PET imaging method to monitor CD8-dependent responses to immunotherapy. Cancer Res 76, 73\u201382 (2016).","journal-title":"Cancer Res"},{"key":"133_CR25","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","volume":"24","author":"F Bench","year":"2018","unstructured":"Bench, F. et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat. Med. 24, 1852\u20131858 (2018).","journal-title":"Nat. Med."},{"key":"133_CR26","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.7150\/thno.79976","volume":"13","author":"J Schwenck","year":"2023","unstructured":"Schwenck, J. et al. In vivo imaging of CD8+ T cells in metastatic cancer patients: first clinical experience with simultaneous [89Zr]Zr-Df-IAB22M2C PET\/MRI. Theranostics 13, 2408\u20132423 (2023).","journal-title":"Theranostics"},{"key":"133_CR27","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41416-018-0152-4","volume":"119","author":"AK Berger","year":"2018","unstructured":"Berger, A. K. et al. Early metabolic response in sequential FDG-PET\/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: Results of the phase II REMOTUX trial. Br. J. Cancer 119, 170\u2013175 (2018).","journal-title":"Br. J. Cancer"},{"key":"133_CR28","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1101\/sqb.2012.76.010900","volume":"76","author":"MG Vander Heiden","year":"2011","unstructured":"Vander Heiden, M. G. et al. Metabolic pathway alterations that support cell proliferation. Cold Spring Harb. Lab. Press. 76, 325\u2013334 (2011).","journal-title":"Cold Spring Harb. Lab. Press."},{"key":"133_CR29","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1084\/jem.20121061","volume":"209","author":"WR Austin","year":"2012","unstructured":"Austin, W. R. et al. Nucleoside Salvage Pathway Kinases Regulate Hematopoiesis by Linking Nucleotide Metabolism with Replication Stress. J. Exp. Med. 209, 2215\u20132228 (2012).","journal-title":"J. Exp. Med."},{"key":"133_CR30","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/3337","volume":"4","author":"AF Shields","year":"1998","unstructured":"Shields, A. F. et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat. Med 4, 1334\u20131336 (1998).","journal-title":"Nat. Med"},{"key":"133_CR31","doi-asserted-by":"publisher","first-page":"340","DOI":"10.2967\/jnumed.109.070946","volume":"51","author":"A Ribas","year":"2010","unstructured":"Ribas, A. et al. Imaging of CTLA4 blockade\u2013induced cell replication with 18F-FLT PET in patients with advanced melanoma treated with tremelimumab. J. Nucl. Med. 51, 340\u2013346 (2010).","journal-title":"J. Nucl. Med."},{"key":"133_CR32","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1158\/0008-5472.CAN-19-0267","volume":"79","author":"J Levi","year":"2019","unstructured":"Levi, J. et al. Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-PD-1 Therapy. Cancer Res. 79, 3455\u20133465 (2019).","journal-title":"Cancer Res."},{"key":"133_CR33","doi-asserted-by":"publisher","first-page":"802","DOI":"10.2967\/jnumed.120.249078","volume":"62","author":"J Levi","year":"2021","unstructured":"Levi, J. et al. 18F-AraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy. J. Nucl. Med. 62, 802\u2013807 (2021).","journal-title":"J. Nucl. Med."},{"key":"133_CR34","first-page":"1869","volume":"65","author":"J Levi","year":"2024","unstructured":"Levi, J. et al. [18F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non\u2013Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy. J. Nucl. Med. 65, 1869\u20131875 (2024).","journal-title":"J. Nucl. Med."},{"key":"133_CR35","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.2967\/jnumed.109.073361","volume":"51","author":"CJ Shu","year":"2010","unstructured":"Shu, C. J. et al. Novel PET probes specific for deoxycytidine kinase. J. Nucl. Med. 51, 1092\u20131098 (2010).","journal-title":"J. Nucl. Med."},{"key":"133_CR36","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nm1724","volume":"14","author":"CG Radu","year":"2008","unstructured":"Radu, C. G. et al. Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2\u2019-deoxycytidine analog. Nat. Med. 14, 783\u2013788 (2008).","journal-title":"Nat. Med."},{"key":"133_CR37","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.2967\/jnumed.118.210328","volume":"59","author":"JR Salas","year":"2018","unstructured":"Salas, J. R. et al. 18F-FAC PET Selectively Images Liver-Infiltrating CD4 and CD8 T Cells in a Mouse Model of Autoimmune Hepatitis. J. Nucl. Med. 59, 1616\u20131623 (2018).","journal-title":"J. Nucl. Med."},{"key":"133_CR38","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2967\/jnumed.119.229351","volume":"61","author":"BY Chen","year":"2019","unstructured":"Chen, B. Y. et al. 18F-FAC PET visualizes brain-infiltrating leukocytes in a mouse model of multiple sclerosis. J. Nucl. Med. 61, 757\u2013763 (2019).","journal-title":"J. Nucl. Med."},{"key":"133_CR39","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1073\/pnas.1524212113","volume":"113","author":"W Kim","year":"2016","unstructured":"Kim, W. et al. [18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity. Proc. Natl. Acad. Sci. USA. 113, 4027\u20134032 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"133_CR40","doi-asserted-by":"publisher","first-page":"10220","DOI":"10.1073\/pnas.1706689114","volume":"114","author":"JP Antonios","year":"2017","unstructured":"Antonios, J. P. et al. Detection of immune response after immunotherapy in glioblastoma using PET and MRI. Proc. Natl. Acad. Sci. USA. 114, 10220\u201310225 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"133_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01900-0","volume":"22","author":"P Knopf","year":"2023","unstructured":"Knopf, P. et al. Acidosis-mediated increase in IFN-\u03b3-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors. Mol. Cancer 22, 207 (2023).","journal-title":"Mol. Cancer"},{"key":"133_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02424-0","volume":"9","author":"M Efremova","year":"2018","unstructured":"Efremova, M. et al. Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution. Nat. Commun. 9, 32 (2018).","journal-title":"Nat. Commun."},{"key":"133_CR43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.imlet.2017.08.024","volume":"191","author":"SY Owyang","year":"2017","unstructured":"Owyang, S. Y. et al. The effect of CT26 tumor-derived TGF-\u03b2 on the balance of tumor growth and immunity. Immunol. Lett. 191, 47\u201354 (2017).","journal-title":"Immunol. Lett."},{"key":"133_CR44","doi-asserted-by":"publisher","first-page":"11774","DOI":"10.1073\/pnas.1410626111","volume":"111","author":"K Kim","year":"2014","unstructured":"Kim, K. et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl. Acad. Sci. USA. 111, 11774\u201311779 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"133_CR45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/iep.12114","volume":"96","author":"C Danciu","year":"2015","unstructured":"Danciu, C. et al. Behaviour of four different B16 murine melanoma cell sublines: C57BL\/6J skin. Int. J. Exp. Pathol. 96, 73\u201380 (2015).","journal-title":"Int. J. Exp. Pathol."},{"key":"133_CR46","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","volume":"162","author":"S Kleffel","year":"2015","unstructured":"Kleffel, S. et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell 162, 1242\u20131256 (2015).","journal-title":"Cell"},{"key":"133_CR47","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3389\/fonc.2019.00685","volume":"9","author":"GCM Evangelista","year":"2019","unstructured":"Evangelista, G. C. M. et al. 4T1 mammary carcinoma colonization of metastatic niches is accelerated by obesity. Front. Oncol. 9, 685 (2019).","journal-title":"Front. Oncol."},{"key":"133_CR48","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1053\/j.gastro.2010.01.003","volume":"138","author":"S Brewer","year":"2010","unstructured":"Brewer, S. et al. Epithelial uptake of [18F]1-(2\u2019-deoxy-2\u2019-arabinofuranosyl) cytosine indicates intestinal inflammation in mice. Gastroenterology 138, 1266\u20131275 (2010).","journal-title":"Gastroenterology"},{"key":"133_CR49","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10517-011-1268-1","volume":"151","author":"GV Trunova","year":"2011","unstructured":"Trunova, G. V. et al. Morphofunctional Characteristic of the Immune System in BALB\/c and C57Bl\/6 Mice. Bull. Exp. Biol. Med. 151, 99\u2013102 (2011).","journal-title":"Bull. Exp. Biol. Med."},{"key":"133_CR50","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","volume":"49","author":"CS Garris","year":"2018","unstructured":"Garris, C. S. et al. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-\u03b3 and IL-12. Immunity 49, 1148\u20131161.e7 (2018).","journal-title":"Immunity"},{"key":"133_CR51","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","volume":"25","author":"JJ Luke","year":"2019","unstructured":"Luke, J. J. et al. WNT\/\u03b2-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clin. Cancer Res. 25, 3074\u20133083 (2019).","journal-title":"Clin. Cancer Res."},{"key":"133_CR52","doi-asserted-by":"publisher","first-page":"925","DOI":"10.7150\/thno.35989","volume":"10","author":"J Schwenck","year":"2020","unstructured":"Schwenck, J. et al. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo 18F-FDG-PET. Theranostics 10, 925\u2013937 (2020).","journal-title":"Theranostics"},{"key":"133_CR53","doi-asserted-by":"publisher","first-page":"e000656","DOI":"10.1136\/jitc-2020-000656","volume":"8","author":"F Seith","year":"2020","unstructured":"Seith, F. et al. Is there a link between very early changes of primary and secondary lymphoid organs in 18F-FDG-PET\/MRI and treatment response to checkpoint inhibitor therapy? J. Immunother. Cancer 8, e000656 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"133_CR54","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s11307-022-01781-7","volume":"25","author":"H Alsaid","year":"2023","unstructured":"Alsaid, H. et al. Immuno-PET Monitoring of CD8+ T Cell Infiltration Post ICOS Agonist Antibody Treatment Alone and in Combination with PD-1 Blocking Antibody Using a 89Zr Anti-CD8+ Mouse Minibody in EMT6 Syngeneic Tumor Mouse. Mol. Imaging Biol. 25, 528\u2013540 (2023).","journal-title":"Mol. Imaging Biol."},{"key":"133_CR55","doi-asserted-by":"publisher","first-page":"11309","DOI":"10.1073\/pnas.1710466114","volume":"114","author":"J Collins","year":"2017","unstructured":"Collins, J. et al. Production of diverse PET probes with limited resources: 24 18F-labeled compounds prepared with a single radiosynthesizer. Proc. Natl. Acad. Sci. USA. 114, 11309\u201311314 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"133_CR56","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1021\/acs.oprd.9b00414","volume":"24","author":"UP Aher","year":"2020","unstructured":"Aher, U. P. et al. Large-Scale Stereoselective Synthesis of 1,3-Oxathiolane Nucleoside, Lamivudine, via ZrCl4-Mediated N-Glycosylation. Org. Process. Res. Dev. 24, 387\u2013397 (2020).","journal-title":"Org. Process. Res. Dev."},{"key":"133_CR57","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1148\/radiol.2443061756","volume":"244","author":"MS Judenhofer","year":"2007","unstructured":"Judenhofer, M. S. et al. Simultaneous PET\/MR images, acquired with a compact MRI-compatible PET detector in a 7 Tesla magnet. Radiology 244, 807\u2013814 (2007).","journal-title":"Radiology"},{"key":"133_CR58","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nm1700","volume":"14","author":"MS Judenhofer","year":"2008","unstructured":"Judenhofer, M. S. et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat. Med. 14, 459\u2013465 (2008).","journal-title":"Nat. Med."},{"key":"133_CR59","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20232104","volume":"221","author":"M Ruggiu","year":"2024","unstructured":"Ruggiu, M. et al. Anti-PD-1 therapy triggers Tfh cell\u2013dependent IL-4 release to boost CD8 T cell responses in tumor-draining lymph nodes. J. Exp. Med. 221, e20232104 (2024).","journal-title":"J. Exp. Med."}],"container-title":["npj Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44303-025-00133-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44303-025-00133-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44303-025-00133-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T14:02:16Z","timestamp":1767708136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44303-025-00133-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["133"],"URL":"https:\/\/doi.org\/10.1038\/s44303-025-00133-8","relation":{},"ISSN":["2948-197X"],"issn-type":[{"value":"2948-197X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"8 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gregory Bowden is a Guest Editor for npj imaging, but was not involved in the editorial review of, or the decision to publish this article. All other authors declare no competing interests. At the time of this study, Philipp Knopf was a PhD student at the University of Tuebingen and is now employed by Boehringer Ingelheim Pharma GmbH & Co. KG. The authors declare that they have no competing financial or non-financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}